Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedarone - fibrillazione atriale - terapia cardiaca - multaq è indicato per il mantenimento del ritmo sinusale dopo riuscita cardioversione in pazienti adulti clinicamente stabili con fibrillazione atriale parossistica o persistente (af). a causa del suo profilo di sicurezza, multaq deve essere prescritto solo dopo aver preso in considerazione opzioni terapeutiche alternative. multaq non deve essere somministrato a pazienti con disfunzione sistolica ventricolare sinistra o a pazienti con attuali o precedenti episodi di insufficienza cardiaca.

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - dronedaronum - compresse rivestite con film di 400 mg di dronedarone - dronedaronum 400 mg a dronedaroni hydrochloridum 426 mg, hypromellosum, maydis per amylum, crospovidonum, poloxamerum 407, lactosum monohydricum 41.65 mg, silice colloidalis anhydrica, magnesio stearas, pellicule: hypromellosum, macrogolum 6000, cera carnauba, colore.: e 171, per compresso haze. - antiarythmique - synthetika

Ιταλία - Ιταλικά - Ministero della Salute

multimedical srl - prolunghe a bassa pressione

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - interferonum beta-1a adnr - soluzione iniettabile in cartucce - interferonum beta-1a adnr 66 µg corresp. 18 mio u.i., alcohol benzylicus 7.5 mg, mannitolum, methioninum, poloxamerum 188, natrii acetas trihydricus, acidum aceticum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1.5 ml corresp. natrium max. 0.04 mg. - multiple sklerose - biotechnologika

Ελβετία - Ιταλικά - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - interferonum beta-1a adnr - soluzione iniettabile in cartucce - interferonum beta-1a adnr 132 µg corresp. 36 mio u.i., alcohol benzylicus 7.5 mg, mannitolum, methioninum, poloxamerum 188, natrii acetas trihydricus, acidum aceticum, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 1.5 ml corresp. natrium max. 0.06 mg. - multiple sklerose - biotechnologika

Ιταλία - Ιταλικά - Ministero della Salute

sharda cropchem limited - tebuconazolo; - granulare idrodispersibile - 25.0 g i valori indicati sono per 100 g di prodotto. - fungicida

Ιταλία - Ιταλικά - AIFA (Agenzia Italiana del Farmaco)

farmaceutici caber s.r.l. - flunisolide - flunisolide

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosoppressori - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosoppressori - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Ευρωπαϊκή Ένωση - Ιταλικά - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosoppressori - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) è indicato per il trattamento di pazienti adulti con mieloma multiplo precedentemente non trattato e che non sono idonei per il trapianto. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 e 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).